|
| | 10100SJ0043 Engrossed | | LRB101 11737 MST 58399 r |
|
|
1 | | SENATE JOINT RESOLUTION NO. 43 |
2 | | (As Amended by Senate Amendment No. 1)
|
3 | | WHEREAS, The human papillomavirus (HPV) is the most common |
4 | | sexually transmitted virus in the United
States; nearly 14 |
5 | | million people become infected each year; and |
6 | | WHEREAS, HPV causes approximately 33,700 cases of |
7 | | HPV-associated cancers each year, including
cervical, anal, |
8 | | and oropharyngeal cancers; and |
9 | | WHEREAS, 9-valent HPV vaccine protects against nine types |
10 | | of HPV infection; and |
11 | | WHEREAS, The HPV vaccine was tested before being licensed |
12 | | by the Food and Drug
Administration and continues to be |
13 | | monitored by the Centers for Disease Control and
Prevention and |
14 | | the Food and Drug Administration; and |
15 | | WHEREAS, The most common side effects are mild and include |
16 | | pain, redness, or swelling in the arm where the shot is given; |
17 | | dizziness, fainting, nausea, and headaches can also occur; and |
18 | | WHEREAS, The American Academy of Pediatrics (AAP) and the |
19 | | Advisory Committee on Immunization
Practices (ACIP) recommend |
20 | | two doses of HPV vaccine for males and females ages 11-12; the
|